Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. - Wikidata - awgldk - TriplyDB

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.

http://www.wikidata.org/entity/Q38071119

about

Molecular therapy of colorectal cancer: progress and future directions Standard chemotherapy with cetuximab for treatment of colorectal cancer MicroRNA-106b promotes colorectal cancer cell migration and invasion by directly targeting DLC1 MiR-21/RASA1 axis affects malignancy of colon cancer cells via RAS pathways The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer MicroRNA-378-5p suppresses cell proliferation and induces apoptosis in colorectal cancer cells by targeting BRAF Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer.AXL is an oncotarget in human colorectal cancer.The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model.Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.Increasing the α 2, 6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer.Impact of cetuximab in current treatment of metastatic colorectal cancer.Advances and new perspectives in the treatment of metastatic colon cancer.The role of cell-free DNA in predicting colorectal cancer prognosis.X-linked inhibitor of apoptosis-associated factor l (XAFl) enhances the sensitivity of colorectal cancer cells to cisplatin.High-sensitivity PCR method for detecting BRAF V600E mutations in metastatic colorectal cancer using LNA/DNA chimeras to block wild-type alleles.EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients.EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features.[EGFR inhibition in NSCLC tumor cell lines : Influence on cell cycle and tumor control].Molecular profiling in colorectal cancer: current state of play and future directions

P2860

Q27005764-C1ED7A39-0389-4A76-9427-BCAC849CE886 Q28088693-61728987-DC07-44FB-9590-99DF72482B8C Q28384675-26B6EB68-EB35-4814-A13C-EBFEAC2362FA Q35045730-E261CEDE-9CE6-4BC9-9161-DABA26BB5CFB Q35068059-8F8B4F74-DF59-4D37-8492-BF165CD7F273 Q35521281-B2510E3E-794F-4637-8AEE-3A14FDB577AB Q35606229-2EE40046-C144-4AFD-A405-0B202F1D0B3B Q36195351-78E596BE-76C0-42BA-92DF-7166553CC9D2 Q36414168-4FBC0365-9A56-4DC7-8332-67D62B887279 Q37130603-158AE4B4-C12D-4218-8C1C-2E9631659880 Q37204600-CF313E4F-4F4B-4446-A283-1C903CD653E1 Q37697540-651655DF-9A14-4E6F-8D0F-658D6830A9D9 Q38169157-BD9CDCCD-B2FE-4587-9285-D8955BD3B2BA Q38183447-7D365E80-20EA-4D87-9F9B-CFEA3EF13909 Q38229589-B0B1385F-BC13-44D1-AA2C-07BD70C3F1CD Q38637642-B9C5C256-DCFD-45BD-80D4-8AC8C155C9B5 Q38943031-9627E27F-2F52-4992-9D65-B3C38A9A3642 Q39026752-F0101946-C066-4E30-9324-1EEF13971E10 Q44702301-8D840EC3-04CD-4422-88A4-D62DCE1D9C1B Q47763091-CC401C95-2927-4F9C-A62F-0208DB0EB25B Q54194984-6D2ADDC0-BBC2-4776-80DB-82D84BF31E8E Q54687516-8BA664D1-2030-45A9-8A5F-7F1BF3830EFB

P2860

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.

http://www.wikidata.org/entity/Q38071119

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Optimizing treatment of metast ...... sms of cancer cell resistance.

@en

type

label

Optimizing treatment of metast ...... sms of cancer cell resistance.

@en

prefLabel

Optimizing treatment of metast ...... sms of cancer cell resistance.

@en

P1433

Q38071119-3BBFC93E-0EB1-45F0-A62E-5BBE7A20263F

P1476

Q38071119-0E993EF4-A413-4884-8E69-68DC24797B9E

P2093

Q38071119-671E3CAF-046E-46AD-8F20-A4C452463BDE

Q38071119-ADC3C8B3-4E09-41FE-A7C8-108462BE97F6

Q38071119-F0FBD6AA-DAB1-4738-BCD7-08C6329C642D

P2860

Q38071119-034EA8FC-1AC6-4226-BFEC-C3F9861A1F13

Q38071119-039A74D5-D6FB-415F-9EF8-FF3177F6B66F

Q38071119-0799770D-3717-4AD0-8087-8413B3EA69B6

Q38071119-10B6EC54-A9C2-42CA-9214-E0C11CE9BDCB

Q38071119-13DDB58F-2DFE-437A-B62B-778472F2EAB2

Q38071119-18B2F341-ECDC-407E-A9EF-C3BB68D444F7

Q38071119-1EA07A3E-62D4-4CC6-9122-22D26046226D

Q38071119-1EF54F16-194C-4958-843D-A2279DBC6B0B

Q38071119-2740836A-F50E-4C63-9D94-C14A99657EC9

Q38071119-2B1838D7-465C-43AD-89C2-A14324BC6939

P304

Q38071119-9076098D-3757-4138-A179-6A95A5D12E96

P31

Q38071119-E59A8DD9-3231-40BF-8862-382BE57D83AE

P356

Q38071119-E93B5668-DD71-4BCB-A316-3FBD11B91C7D

P407

Q38071119-8149DB6D-828A-451F-895A-F6292ADBB97A

P433

Q38071119-055B346F-032B-415F-B651-24FEEBA84470

P478

Q38071119-89F8B96E-F2D9-4A88-8C4E-343875137029

P50

Q38071119-48DEC589-2B0A-4F7C-B2D6-2AD055D00403

Q38071119-9970EE88-66AF-4CF6-9A98-20EBEACA8F08

Q38071119-B905004E-FAC3-4B6D-A0D4-711C9CB83A52

Q38071119-DB533FDE-4E26-40F9-ADF8-06D2085558CA

P577

Q38071119-E90C17DA-8D94-41F8-AFC2-B848CA17F7DA

P5875

Q38071119-3A1FB97F-5F31-4094-B221-30515FD50FA6

P698

Q38071119-5488EB78-D77C-426C-8416-9189D4F586E2

P921

Q38071119-611FD4CC-D5B0-4011-9B2B-1D7884A5344C

Q38071119-E31D5471-64A6-4E83-822D-661D6ED8DECC

P356

14712598.2012.756469

P1433

Expert Opinion on Biological Therapy

P1476

Optimizing treatment of metast ...... isms of cancer cell resistance

@en

P2093

Erika Martinelli

http://www.w3.org/2001/XMLSchema#string

Santolo R Addeo

http://www.w3.org/2001/XMLSchema#string

Silvia Zappavigna

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

P304

241-255

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2012.756469

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Michele Caraglia

Fortunato Ciardiello

P577

2013-01-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234041713

http://www.w3.org/2001/XMLSchema#string

P698

23281932

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer